Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Parallel Design, Placebo-controlled, Phase 2 Clinical Trial and Open-Label Extension Study to Evaluate the Safety and Efficacy for BEY2153 in Patients with Early Alzheimer's Disease

NCT06885567 is registered in ClinicalTrials.gov with BeyondBio Inc. as lead sponsor.

NCT NCT06885567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06885567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Parallel Design, Placebo-controlled, Phase 2 Clinical Trial and Open-Label Extension Study to Evaluate the Safety and Efficacy for BEY2153 in Patients with Early Alzheimer's Disease
Lead sponsor
BeyondBio Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
August 31, 2028
Enrollment
90 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, alzheimer' disease